Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility

International Journal of Antimicrobial Agents

Volumn 29, Issue 4, 2007, Pages 389-396

  Cattoir, Vincent ^a   Nectoux, Juliette ^a   Lascols, Christine ^a   Deforges, Lionel ^a   Delchier, Jean Charles ^a   Megraud, Francis ^b   Soussy, Claude James ^a   Cambau, Emmanuelle ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

DNA gyrase; gyrA polymorphism; Helicobacter pylori; Molecular diagnosis; QRDR; Quinolones

Indexed keywords

AMOXICILLIN; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; ISOLEUCINE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NALIDIXIC ACID; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; THREONINE; TYROSINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; ENZYME POLYMORPHISM; GENE SEQUENCE; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL;

EID: 33847655711     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.11.007     Document Type: Article

References (35)

1. Versalovic J., and Fox J. Helicobacter. In: Murray P. (Ed). Manual of clinical microbiology (2003), ASM Press, Washington, DC
2. Dunn B.E., Cohen H., and Blaser M.J. Helicobacter pylori. Clin Microbiol Rev 10 (1997) 720-741
3. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
4. Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006:CD003840.
5. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41 (1997) 8-13
6. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 64 (2004) 1893-1904
7. Glupczynski Y., Megraud F., Lopez-Brea M., et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20 (2001) 820-823
8. Adamek R.J., Suerbaum S., Pfaffenbach B., et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 93 (1998) 386-389
9. Kim J.M., Kim J.S., Jung H.C., et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48 (2004) 4843-4847
10. Kim J.M., Kim J.S., Kim N., et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 28 (2006) 6-13
11. Cianci R., Montalto M., Pandolfi F., et al. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 12 (2006) 2313-2319
12. Nista E.C., Candelli M., Zocco M.A., et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21 (2005) 1241-1247
13. Sanchez J.E., Saenz N.G., Rincon M.R., et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 46 (2000) 283-285
14. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40 (1997) 639-651
15. Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 5 (2005) 67-72
16. Sharara A.I., Chaar H.F., Racoubian E., et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 9 (2004) 255-261
17. Nishizawa T., Suzuki H., Kurabayashi K., et al. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 50 (2006) 1538-1540
18. Tankovic J., Lascols C., Sculo Q., et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47 (2003) 3942-3944
19. Cabrita J., Oleastro M., Matos R., et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46 (2000) 1029-1031
20. Hooper D. Mechanisms of quinolone resistance. In: Hooper D., and Rubinstein E. (Eds). Quinolone antimicrobial agents (2003), ASM Press, Washington, DC
21. Moore R.A., Beckthold B., Wong S., et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39 (1995) 107-111
22. Wang G., Wilson T.J., Jiang Q., et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 45 (2001) 727-733
23. Glocker E., and Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 42 (2004) 2241-2246
24. Bina J.E., Alm R.A., Uria-Nickelsen M., et al. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 44 (2000) 248-254
25. Alm R.A., Ling L.S., Moir D.T., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397 (1999) 176-180 [Erratum. Nature 1999;397:719]
26. Tomb J.F., White O., Kerlavage A.R., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 (1997) 539-547
27. Falsafi T., Mobasheri F., Nariman F., et al. Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 42 (2004) 387-389
28. Goossens H., Ferech M., Van der Stichele R., et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 (2005) 579-587
29. Fujimura S., Kato S., Iinuma K., et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 53 (2004) 1019-1022
30. Truong Q.C., Nguyen Van J.C., Shlaes D., et al. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents Chemother 41 (1997) 85-90
31. Ricci V., Peterson M.L., Rotschafer J.C., et al. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob Agents Chemother 48 (2004) 1344-1346
32. Guillemin I., Jarlier V., and Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 42 (1998) 2084-2088
33. 87. Antimicrob Agents Chemother 45 (2001) 1994-2000
34. Brosch R., Gordon S.V., Marmiesse M., et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 99 (2002) 3684-3689
35. Engberg J., Aarestrup F.M., Taylor D.E., et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 7 (2001) 24-34